Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program.

Carel W le Roux,Shuyu Zhang,Louis J Aronne,Robert F Kushner,Ariana M Chao,Sriram Machineni,Julia Dunn, Farai B Chigutsa,Nadia N Ahmad,Mathijs C Bunck

Obesity (Silver Spring, Md.)（2023）

引用 10|浏览14

暂无评分

摘要

The extensive assessment of once-weekly tirzepatide in the global SURMOUNT program will detail the clinical effects of this first-in-class glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist in chronic weight management.

查看译文

关键词

obesity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要